EUCTR2011-001918-34-AT进行中（未招募）不适用
An open, single-centre, controlled trial to investigate the efficacy and usability of published best practice to control glycaemia in hospitalised patients with type 2 diabetes
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Informed consent obtained after being advised of the nature of the study
- •Male or female aged 18 - 90 years (both inclusive)
- •Type 2 diabetes (diagnosed at least 3 months prior to study start) treated with diet, oral agents, non-insulin injected anti-diabetic medicine, insulin therapy or any combination of the four
- •Blood glucose in the range between 140 – 400 mg/dl (both inclusive)
- •Expected stay = 48 hours
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 34
排除标准
- •Hyperglycemia without known history of type 2 diabetes mellitus
- •Impaired renal function (serum creatinine =3.0mg/dL)
- •Clinically relevant hepatic disease
- •Presence or history of diabetic ketoacidosis
- •Any mental condition rendering the patient incapable of giving his consent
- •Terminally ill patients
- •Participation in a trail within 3 months prior to this trail
- •Known or suspected allergy to insulin
研究者
相似试验
进行中（未招募）
不适用
A monocentre, open-label, prospective study investigating the effects of the human normal immunoglobulin Intratect®/ BT 681 for intravenous administration on clinical efficacy, safety, and laboratory parameters in patients with chronic idiopathic pain syndromes.Chronic idiopathic pain syndromes (fibromyalgia, myofascial pain, complex regional pain syndrome)MedDRA version: 8.1Level: PTClassification code 10033371EUCTR2005-004918-32-DEBiotest AG
已完成
不适用
An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination with Pembrolizumab, with or without Chemotherapy, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer10027476Lung CancerNon-Small Cell Lung CancerNL-OMON46066IO Biotech Aps16
进行中（未招募）
1 期
A study investigating the use of IO102 in combination with pembrolizumab, with or without chemotherapy, for patients with metastatic non-small cell lung cancer.Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000139-28-DEIO Biotech Aps108
进行中（未招募）
1 期
A study investigating the use of IO102 in combination with pembrolizumab, with or without chemotherapy, for patients with metastatic non-small cell lung cancer.EUCTR2018-000139-28-ESIO Biotech Aps108
进行中（未招募）
1 期
A study investigating the use of IO102 in combination with pembrolizumab, with or without chemotherapy, for patients with metastatic non-small cell lung cancer.Metastatic Non-Small Cell Lung CancerEUCTR2018-000139-28-NLIO Biotech Aps108